Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or III symptoms and a left ventricular ejection fraction less than or equal to 40% were enrolled in the study and were randomized to receive either placebo, 50mg, 150mg or 300mg of trientine-HCL twice daily.
Results suggest a 20% reduction in NTproBNP at 4 and 8 weeks and improvement in 6-minute walk distance and KCCQ-OSS in the 300mg cohort.
Recorded on-site at HFA 2023, Prague.
Visit Radcliffe Cardiology:
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook:
Follow us on Twitter:
Музыка
Фильмы
ТВ Шоу
Категории видео
